Roundup: Diabetes news from Livongo, Abbott, and Senseonics

By Jonah Comstock
03:50 pm

Today was a big day in the world of diabetes management technology, with major announcements from Abbott, Livongo, and Senseonics. Read on below for a round-up of diabetes news.

Livongo acquires Diabeto

Mountain View, California-based Livongo Health, the chronic condition management technology company founded by former Allscripts CEO Glen Tullman, has acquired Diabeto, a diabetes management company based in Piscataway, New Jersey in the US and Maharashtra in India. The terms of the acquisition were not disclosed. The acquisition will give Livongo users the ability to connect their existing meters rather than switch to Livongo’s cellular-connected meter, if they’d prefer. More.

NHS to reimburse Abbott’s Freestyle Libre glucometer

The UK’s National Health Service Business Services Authority has approved Abbott’s FreeStyle Libre system for reimbursement effective November 1.

The FreeStyle Libre system is notable because it doesn't require fingersticks to calibrate and it has a lower cost than other CGMs on the market. The user wears a tiny insertable sensor and a patch on their arm for up to 14 days. The patch records glucose data every 15 minutes and uses NFC technology to transmit the data to a smartphone.

"The FreeStyle Libre system has been shown to offer life-changing improvements for people with diabetes to help them live healthier and fuller lives," Neil Harris, general manager of Abbott's UK diabetes care business, said in a statement. "We are delighted with the NHS decision, and we look forward to partnering with them to provide people with diabetes our innovative technology to help manage their condition.”

Senseonics gets CE Mark for Eversense XL

Eversense XL, a new version of Senseonics' implantable continuous glucose monitor that lasts 180 days rather than 90, has received a CE Mark, allowing it to be marketed in Europe.

“When we introduced the Eversense System last year, we were providing the longest-wear sensor with up to 90-day wear for people with diabetes,” CEO Tim Goodnow said in a statement. “Now with the new Eversense XL System’s even longer sensor duration, patients can extend a single sensor wear over 3 seasons – inserting a new sensor in the Fall which will continue through the Winter to be replaced in Spring.”

The company intends to launch the XL product in Europe in the fourth quarter of 2017. The company is still waiting on FDA clearance for its first generation sensor, but has been launched in a number of European companies since last fall.


The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!